Onglyza 2.5 mg (Saxagliptin) – Product Overview

Onglyza 2.5 mg is a prescription oral medication indicated for the management of type 2 diabetes mellitus. Manufactured by AstraZeneca Pharma India Ltd, the tablet contains saxagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor that enhances the activity of incretin hormones. Each strip contains 14 tablets, and the product is available in pack sizes of 28, 56, or 84 tablets to accommodate varying treatment durations. The medication is formulated for once‑daily administration and is intended to be used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes. Clinical studies have demonstrated that Onglyza can reduce hemoglobin A1c (HbA1c) levels without causing excessive hypoglycemia when used as monotherapy or in combination with metformin or sulfonylureas. The drug is not intended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

What is Onglyza?

Onglyza is the brand name for the active ingredient saxagliptin, a selective inhibitor of the enzyme dipeptidyl peptidase‑4 (DPP‑4). By blocking DPP‑4, saxagliptin prevents the rapid degradation of incretin hormones such as glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). These hormones stimulate glucose‑dependent insulin release, suppress glucagon secretion, and slow gastric emptying, collectively contributing to lower post‑prandial glucose levels. The 2.5 mg dosage represents the standard strength approved for adult patients with type 2 diabetes who require additional glycemic control beyond lifestyle modification.

Uses and Benefits

The primary use of Onglyza is to improve glycemic control in adults with type 2 diabetes mellitus when diet and exercise alone are insufficient. Clinical trials have shown that saxagliptin provides modest reductions in HbA1c (approximately 0.5% to 0.8% on average) and helps attenuate post‑prandial glucose spikes. Because it is glucose‑dependent, the risk of hypoglycemia is low when used without insulin or sulfonylureas. Additional benefits include weight neutrality and a favorable safety profile compared with some older sulfonylureas. Onglyza is also approved for use in combination with metformin, a sulfonylurea, or a PPAR‑γ agonist, allowing clinicians to tailor therapy to individual patient needs.

How It Works

Saxagliptin exerts its antidiabetic effect by selectively inhibiting the enzyme DPP‑4, which normally degrades incretin hormones. The preservation of GLP‑1 and GIP enhances glucose‑dependent insulin secretion from pancreatic β‑cells and reduces glucagon release when blood glucose rises. This mechanism is “glucose‑dependent,” meaning that the drug’s effect on insulin release diminishes as glucose levels fall, thereby minimizing the potential for hypoglycemia. Saxagliptin also modestly slows gastric emptying, contributing to reduced post‑prandial glucose excursions. The pharmacokinetic profile of saxagliptin includes extensive metabolism via hydrolysis and renal excretion, with a half‑life of approximately 23 hours, supporting once‑daily dosing.

Dosage Guidelines

The recommended starting dose of Onglyza is 2.5 mg taken orally once daily, with or without food. For patients with moderate renal impairment (estimated glomerular filtration rate 30–50 mL/min/1.73 m²), the dose may be reduced to 2.5 mg every other day, but clinical judgment should guide adjustments. In subjects with severe renal impairment (eGFR <30 mL/min/1.73 m²) or those undergoing dialysis, the dose should be reduced to 2.5 mg every other day. The medication should be swallowed whole with a full glass of water. If a dose is missed, the patient should take it as soon as remembered unless it is near the time of the next scheduled dose; in that case, the missed dose should be skipped and therapy resumed at the regular interval. Consistency in dosing helps maintain steady plasma concentrations and optimal glycemic control.

Side Effects

Like all medications, Onglyza can be associated with adverse effects. The most commonly reported side effects include nasopharyngitis, urinary tract infections, and headache. Rare but serious adverse events may involve pancreatitis, severe joint pain, and hypersensitivity reactions such as rash or angioedema. Patients should discontinue the drug and seek medical attention if they experience persistent abdominal pain, vomiting, or signs of an allergic reaction. It is important to note that saxagliptin does not increase the risk of major cardiovascular events, but caution is advised in patients with a history of pancreatitis or known hypersensitivity to the drug or its excipients.

Warnings and Precautions

Before initiating therapy with Onglyza, healthcare providers should assess renal function, as dose adjustments are required in moderate to severe renal impairment. Patients with a history of pancreatitis should be monitored closely, as cases of acute pancreatitis have been reported in association with DPP‑4 inhibitors. Caution is also warranted in individuals with a prior hypersensitivity to saxagliptin or any component of the formulation. Concomitant use with strong CYP3A4 inhibitors or inducers is not expected to significantly affect saxagliptin exposure, but dose modifications are recommended when the drug is used in combination with potent renal excretory modulators. Pregnant or breastfeeding women should only use Onglyza if the potential benefit justifies the potential risk, and they should discuss this with their healthcare provider.

Frequently Asked Questions

1. Can Onglyza be used as a standalone therapy? Yes, Onglyza is approved as monotherapy for type 2 diabetes, but it is often combined with metformin or other oral agents to achieve target glycemic control.
2. Does Onglyza cause weight gain? Clinical studies have shown that saxagliptin is weight‑neutral; it does not typically lead to significant weight gain or loss.
3. Is Onglyza safe for patients with kidney disease? Dosage adjustments are required for moderate to severe renal impairment. Patients with an eGFR below 30 mL/min/1.73 m² should use a reduced dosing schedule and be monitored closely.
4. How does Onglyza compare to other DPP‑4 inhibitors? Saxagliptin has a similar efficacy profile to other DPP‑4 inhibitors such as sitagliptin and linagliptin, but it may be associated with a slightly higher incidence of certain side effects like nasopharyngitis.
5. Where can I find the official prescribing information? The full FDA‑approved label and prescribing details are available at the FDA website and on MedlinePlus.

Related Products

• Esomeprazole 40 mg (Generic)
• Esomeprazole 20mg (Generic)
• Neksium (Esomeprazole)
• Neksium 20mg (Esomeprazole)
• Neksium 40 mg (Esomeprazole)
• Okamet 500 Mg (Metformin)
• Imdur (Isosorbide Mononitrate)
• Imdur 30 mg (Isosorbide Mononitrate)
• Imdur 60 mg (Isosorbide Mononitrate)
• Isosorbide Mononitrate Prolonged Release 60 mg (Generic)
• Isosorbide Mononitrate Prolonged Release 30 mg (Generic)
• Ticagrelor (Generic)